| 125.62 Delayed Data As of Sep 20 |  +1.35 / +1.09%Today’s Change | 78.90 Today|||52-Week Range 130.08 | +46.86% Year-to-Date |
| ASRT vs. ZTS: Which Stock Is the Better Value Option? Sep 20 / Zacks.com - Paid Partner Content | How Will Johnson & Johnson's Opioid Case Ruling Impact Big Pharma Stocks? Sep 05 / MotleyFool.com - Paid Partner Content |
| Buy These 7 Small Drugmakers to Boost Your Portfolio's Health Sep 18 / Zacks.com - Paid Partner Content | Why Is Zoetis (ZTS) Up 5.5% Since Last Earnings Report? Sep 05 / Zacks.com - Paid Partner Content |
| Small Drug Stock Outlook: Innovation Holds the Key to Growth Sep 11 / Zacks.com - Paid Partner Content | Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar? Sep 05 / Zacks.com - Paid Partner Content |
| Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year? Sep 11 / Zacks.com - Paid Partner Content |
| Previous close | 124.27 |
| Today’s open | 124.92 |
| Day’s range | 124.64 - 126.14 |
| Volume | 2,585,539 |
| Average volume (3 months) | 2,002,816 |
| Market cap | $57.8B |
| Earnings growth (last year) | +67.96% |
| Earnings growth (this year) | +14.00% |
| Earnings growth (next 5 years) | +10.50% |
| Revenue growth (last year) | +9.76% |
| P/E ratio | 44.4 |
| Price/Sales | 7.15 |
| Price/Book | 26.56 |
| Next reporting date | November 7, 2019 |
| EPS forecast (this quarter) | $0.89 |
| Annual revenue (last year) | $5.8B |
| Annual profit (last year) | $1.4B |
| Net profit margin | 24.52% |
Sector Health Technology |
Industry Pharmaceuticals: Generic |
Chief Executive Officer & Director Juan Ramón Alaix |
Chief Financial Officer & Executive Vice President Glenn C. David |
Corporate headquarters Parsippany, New Jersey |
